Biologos
Private Company
Funding information not available
Overview
Biologos is a long-established, private contract manufacturer providing critical custom media and buffer solutions to the biologics supply chain. The company differentiates itself through flexibility in batch sizes, fast lead times, and a strong customer retention rate of 98%. Recently acquired by Ampersand Capital Partners in 2024, Biologos is positioned for growth, leveraging its GMP expertise and modern 32,000 sq. ft. facility to support the expanding cell & gene therapy and biopharmaceutical markets.
Technology Platform
GMP manufacturing platform for custom cell culture media, buffers, and reagents, featuring sterile liquid formulation, filtration, fill-finish, and flexible scale-up capabilities in an ISO 13485:2016 certified facility.
Opportunities
Risk Factors
Competitive Landscape
Biologos competes in the crowded biologics CDMO space against large global players (e.g., Lonza, Thermo Fisher) and smaller niche manufacturers. It differentiates through operational flexibility (custom batch sizes, fast turnaround), a focus on customer service, and deep expertise in sterile-fill liquid formulations for media and buffers, carving out a specialized position.